SYNTHACE LIMITED

Active London

Research and experimental development on biotechnology

64 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
S

SYNTHACE LIMITED

Research and experimental development on biotechnology

Founded 31 May 2011 Active London, England 64 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 17 Feb 2026 Next due 31 Jan 2026 3 months overdue
Confirmation
Net assets £-8M £8M 2024 year on year
Total assets £3M £4M 2024 year on year
Total Liabilities £11M £5M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

West Works 195 Wood Lane London W12 7FQ England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for SYNTHACE LIMITED (07652459), an active life sciences and medical technology company based in London, England. Incorporated 31 May 2011. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2019–2024)

Cash in Bank

£439.51k

Decreased by £3.56M (-89%)

Net Assets

-£8.34M

Decreased by £8.39M (-16513%)

Total Liabilities

£10.97M

Increased by £4.54M (+71%)

Turnover

£2.88M

Increased by £371.06k (+15%)

Employees

64

Decreased by 11 (-15%)

Debt Ratio

416%

Increased by 317 (+320%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 6

Investors (4)

Investor NameInvestor SinceParticipating Rounds
Investor 1Sept 2017Series A, Series B
Investor 2Sept 2017Series A, Series B
Investor 3Dec 2018Series C, Series B

Share Capital

Share Capital

Share allotments and capital structure

68 Allotments 251,105,983 Shares £53.95m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
11 Aug 2025100,561,428£4.36m£0.043
11 Aug 2025100,561,428£4.36m£0.043
9 Aug 20253,896£66.232£0.017
18 May 202519,361£19.361£0.001
9 Apr 202579,126£79.126£0.001

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (195)

Sofinnova Crossover I Slp
14.0%
11,266,826
Debussy International Limited
12.8%
10,289,161

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Sofinnova Crossover I Slp

Unknown

Active
Notified 11 Aug 2025
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent

Sofinnova Green Seed Fund

Ceased 21 Sept 2017

Ceased

Group Structure

Group Structure

SYNTHACE LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

1 leasehold 1 total
AddressTenurePrice PaidDate Added
Fourth Floor, West Works Building, 195 Wood Lane, London and car parking spaces (W12 7FQ) HAMMERSMITH AND FULHAM
Leasehold-16 Nov 2021
Fourth Floor, West Works Building, 195 Wood Lane, London and car parking spaces (W12 7FQ)
Leasehold
Added 16 Nov 2021
District HAMMERSMITH AND FULHAM

Documents

Company Filings

DateCategoryDescriptionDocument
8 Apr 2026MiscellaneousReplacement filing of SH01 - 09/08/25 Statement of Capital gbp 180829.846
30 Mar 2026CapitalAllotment of shares (GBP 180,833.179) on 2026-03-25
17 Feb 2026AccountsAnnual accounts made up to 2025-01-31
16 Dec 2025CapitalAllotment of shares (GBP 180,829.846) on 2025-08-09
16 Dec 2025CapitalAllotment of shares (GBP 180,829.846) on 2025-08-09
8 Apr 2026 Miscellaneous

Replacement filing of SH01 - 09/08/25 Statement of Capital gbp 180829.846

30 Mar 2026 Capital

Allotment of shares (GBP 180,833.179) on 2026-03-25

17 Feb 2026 Accounts

Annual accounts made up to 2025-01-31

16 Dec 2025 Capital

Allotment of shares (GBP 180,829.846) on 2025-08-09

16 Dec 2025 Capital

Allotment of shares (GBP 180,829.846) on 2025-08-09

Recent Activity

Latest Activity

Replacement filing of SH01 - 09/08/25 Statement of Capital gbp 180829.846

2 weeks ago on 8 Apr 2026

Allotment of shares (GBP 180,833.179) on 2026-03-25

3 weeks ago on 30 Mar 2026

Annual accounts made up to 2025-01-31

2 months ago on 17 Feb 2026

Allotment of shares (GBP 180,829.846) on 2025-08-09

4 months ago on 16 Dec 2025

Allotment of shares (GBP 180,829.846) on 2025-08-09

4 months ago on 16 Dec 2025